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Abstract
Background: Exacerbations of chronic obstructive pulmonary disease (COPD) are associated with loss of lung
function and poor outcomes for patients. However, there are limited data on the time course of changes in
forced expiratory volume in 1 s (FEV1) preceding the first reported symptom and after the start of an
exacerbation.
Methods: WISDOM was a multinational, randomized, double-blind, active-controlled, 52-week study in patients
with severe-to-very severe COPD. Patients received triple therapy (long-acting muscarinic antagonist and long-
acting β2-agonist/inhaled corticosteroid [ICS]) for 6 weeks, and were randomized to continue triple therapy or
stepwise withdrawal of the ICS (dual bronchodilator group). After suitable training, patients performed daily
spirometry at home using a portable, battery-operated spirometer. In the present post hoc analysis, patients who
continued to perform daily home spirometry and completed at least one measurement per week for a 56-day
period before and after the start of a moderate or severe exacerbation were included. Missing values were
imputed by linear interpolation (intermittent), backfilling (beginning) or carry forward (end). Exacerbation onset
was the first day of a reported symptom of exacerbation.
Results: Eight hundred and eighty-eight patients in the WISDOM study had a moderate/severe exacerbation after
the complete ICS withdrawal visit; 360 of them contributed at least one FEV1 measure per week for the 8 weeks
before and after the event and are included in this analysis.
Mean daily FEV1 began to decline from approximately 2 weeks before the onset of symptoms of an exacerbation,
dropping from 0.907 L (mean Days − 56 to − 36 before the exacerbation) to 0.860 L on the first day of the
exacerbation. After the exacerbation, mean FEV1 improved but did not return to pre-exacerbation levels (mean
Days 36–56 after the exacerbation, 0.875 L).
The pattern of FEV1 changes around exacerbations was similar in the triple therapy and dual bronchodilator
groups, and a similar pattern was seen in moderate and severe exacerbations when analysed separately.
Conclusions: Mean lung function starts to decline prior to the first reported symptoms of an exacerbation, and
does not recover to pre-exacerbation levels 8 weeks after the event.
Trial registration: WISDOM (ClinicalTrials.gov number, NCT00975195).
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Background
Exacerbations of chronic obstructive pulmonary dis-
ease (COPD) are associated with both short-term loss
and long-term decline of lung function [1–3]. Previous
studies have shown that lung function drops at the
time of an exacerbation and does not always fully re-
cover to pre-exacerbation levels [4, 5]. Much of what
is known about the impact of exacerbations on lung
function is from analysing long-term lung function
changes in patients who experienced exacerbations
over the course of a clinical trial, with lung function
measured at scheduled in-clinic visits rather than at
the time of the event [2, 3].
Some studies have measured lung function at the
time of and immediately after an event [6, 7]. How-
ever, there are limited data available on the time
course of lung function changes preceding exacerba-
tions and immediately following exacerbations. See-
mungal et al. [4] showed that peak expiratory flow rate
(PEFR) remains relatively stable before the onset of an
exacerbation, while symptoms already deteriorate. By
contrast, Calverley et al. [8] observed a decrease of
around 8% in peak expiratory flow (PEF) in the 2–3
weeks before an exacerbation.
There remains a need to better understand the spi-
rometric changes around the time of an exacerbation,
as it is currently difficult to identify exacerbations
early. This is of clinical relevance as treating exacerba-
tions earlier is associated with faster recovery and re-
duced risk of hospitalization [9].
The WISDOM study was a 12-month inhaled cor-
ticosteroid (ICS) withdrawal study in patients with
severe-to-very severe COPD. It showed that there was
no increased risk of exacerbations following stepwise
withdrawal of fluticasone propionate in patients re-
ceiving tiotropium and salmeterol [10]. In the
WISDOM study, following suitable training, patients
performed daily spirometry at home, providing an op-
portunity to examine the changes in forced expiratory
volume in 1 s (FEV1) that occur prior to and immedi-
ately after an exacerbation.
The aim of the present post hoc analysis was to
characterize the lung function profile of patients prior
to, during and following the first moderate/severe and
severe exacerbation during the WISDOM trial.
Methods
Study design
The WISDOM study methodology has been pub-
lished previously [10, 11]. In brief, this was a multi-
national, randomized, double-blind, parallel-group,
active-control study. Patients entered a 6-week
triple-therapy run-in with long-acting muscarinic an-
tagonist (LAMA) and long-acting β2-agonist (LABA)/
ICS (tiotropium and salmeterol/fluticasone propion-
ate). Patients were then randomized (study Week 0)
to either continue triple therapy for 52 weeks or to
continue receiving salmeterol and tiotropium (dual
bronchodilator therapy) whilst discontinuing ICS in a
stepwise manner over 12 weeks. ICS were completely
discontinued in this group at Week 12. The primary
endpoint was the time to the first moderate or severe
COPD exacerbation during the 12-month study
period. These results and further post hoc analyses
have been published previously [10, 12, 13]. The
study was performed in accordance with the Declar-
ation of Helsinki, the International Conference on
Harmonisation’s Harmonised Tripartite Guideline for
Good Clinical Practice and local regulations. The
protocol was approved by the ethics research board
of the respective institutions, and all patients pro-
vided written informed consent.
Patients and treatments
Patients were ≥ 40 years of age, were either current or
former smokers, had been diagnosed with severe or
very severe COPD (defined as an FEV1 < 50% of the
predicted volume and < 70% of the forced vital cap-
acity after bronchodilation), and a history of at least
one documented exacerbation in the 12 months prior
to screening. Further inclusion and exclusion criteria
have been reported elsewhere [11].
Patients were randomized to continue receiving tio-
tropium, salmeterol and fluticasone propionate, or to
have fluticasone propionate withdrawn over a 12-week
period (further details are given in the Supplementary
Methods in the Additional file 1).
Exacerbations
Patients completed a simple daily paper diary, record-
ing changes in respiratory symptoms and the use of
medications between visits. Diaries were used to help
patients report symptoms and medication changes to
investigators. Moderate exacerbations were defined as
an increase of at least two lower respiratory tract
symptoms related to COPD (shortness of breath, spu-
tum production [volume], sputum purulence, cough,
wheezing or chest tightness), or the new onset of two
or more such symptoms, with at least one symptom
lasting 3 or more days and for which antibiotics, sys-
temic glucocorticoids or both were prescribed. A se-
vere exacerbation was defined as an exacerbation
requiring hospitalization. The start date of an exacer-
bation was defined as the date of onset of the first
COPD symptom that was part of the exacerbation and
was determined by the investigator reviewing the diary
cards. The end of the exacerbation was determined by
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the investigator reviewing the diary cards and stopping
exacerbation treatment.
In the case of an exacerbation, patients could be
treated with oral glucocorticoids, and/or antibiotics
and further treatments as deemed medically necessary.
Lung function
Following suitable training, patients performed daily spir-
ometry throughout the 52-week study. Home-based mea-
surements were performed by patients each morning
before administration of the study drug using a portable,
battery-operated, ultrasound, transit-time-based electronic
spirometer (EasyOne® NDD Medical Technologies,
Chelmsford, MA, USA, and Zurich, Switzerland). Patients
performed at least three efforts each day, and the highest
FEV1 was selected for analysis [14]. Automatic feedback
was provided to the patient if effort was not in line with
American Thoracic Society (ATS)/European Respiratory
Society (ERS) criteria [15]. Data were retrieved at clinic
visits, and a pulmonologist performed a central over-read
of all lung function data and graded it for acceptability ac-
cording to ATS/ERS criteria. All spirometric techniques
and equipment used were in accordance with ATS/ERS
recommendations [15].
We have previously shown that home-based FEV1 is a
reliable measure, and there was a good agreement be-
tween the home-based spirometry results and the
in-clinic spirometry in the WISDOM trial. However, the
home-based measures of FEV1 were consistently ap-
proximately 50 mL lower than in-clinic values [14].
Statistical analysis
For the present post hoc analysis, we calculated abso-
lute and percentage change from pre-exacerbation
period baseline (mean of the period 6–8 weeks before
the exacerbation) in on-treatment daily FEV1 for 8
weeks before and after the first day of the first moder-
ate/severe on-treatment COPD exacerbation, as well
as change in on-treatment daily FEV1 in the subsets of
moderate and severe on-treatment COPD exacerba-
tions. We also calculated weekly means for FEV1 and
the change from Week − 8.
No inferential statistical analyses were conducted.
Descriptive statistics were calculated for demographic
variables. Data for change in on-treatment daily and
weekly FEV1 up to and following the first day of the
first exacerbation (moderate, moderate/severe and
severe) were plotted graphically for visual interpret-
ation. For this analysis, patients who had at least one
measurement per week in a 56-day period before and
after the start of a moderate or severe exacerbation
were included. Missing values were imputed by linear
interpolation (intermittent), backfilling (beginning) or
carry forward (end).
The analysis includes patients’ first exacerbation after
the ICS withdrawal visit.
Results
Patients
Of 2488 patients randomized into the WISDOM study, 888
experienced a moderate/severe exacerbation between Week
12 (the time of complete ICS withdrawal) and Week 52; 182
patients experienced severe exacerbations. Of the patients
with a moderate/severe exacerbation, a total of 360 patients
completed at least one lung function measurement per week
in the 8weeks prior to and after the exacerbation, so were
included in this analysis: 317 with moderate exacerbations
and 43 with severe exacerbations. The number of exacerba-
tions occurring during triple therapy was similar to those
occurring during dual bronchodilation. The demographics
of the patients included in this analysis are shown in Table 1;
patients were predominantly male (78.9%) and had a mean
age of 63.7 years. Mean in-clinic post-bronchodilator FEV1
at screening was 0.923 L (32.7% predicted).
The demographics of the patients who provided FEV1
data in this analysis are similar to the demographics of the
Table 1 Descriptive statistics for patients included in this
analysis and for all treated patients in the WISDOM population
Analysis All treated
Patients, n 360 2485
Males, n (%) 284 (78.9) 2049 (82.5)
Age, mean years (SD) 63.7 (8.5) 63.8 (8.5)
BMI, mean kg/m2 (SD) 25.4 (5.4) 25.2 (5.1)
COPD duration, mean years (SD) 8.7 (6.2) 7.9 (6.2)
Smoking status, n (%)
Former smoker 236 (65.6) 1654 (66.6)
Current smoker 124 (34.4) 831 (33.4)
Smoking history, mean pack-years (SD) 43.0 (21.6) 45.0 (24.3)
In-clinic post-bronchodilator FEV1,
mean L (SD)
0.923 (0.285) 0.933 (0.297)
In-clinic post-bronchodilator FEV1,
mean % predicted (SD)
32.7 (8.4) 32.8 (9.1)
Mean home-measured FEV1 in the period
6–8 weeks before index exacerbation, L (SD)
0.907 (0.321) N/A
GOLD status, n (%)
2 1 (0.3) 1 (0.6)
3 218 (60.6) 101 (58.0)
4 141 (39.2) 72 (41.4)
Number of patients included with a
moderate exacerbation, n (%)
317 (88.1) N/A
Number of patients included with a
severe exacerbation, n (%)
43 (11.9) N/A
BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV1,
forced expiratory volume in 1 s; GOLD, Global Initiative for Chronic Obstructive
Lung Disease; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA,
long-acting muscarinic antagonist; N/A, not applicable; SD, standard deviation
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wider population of patients in WISDOM (Additional file
2: Table S1) [10]. The mean (standard deviation [SD]) dur-
ation of moderate exacerbations was 18 (31) days; for se-
vere exacerbations, it was 25 (28) days.
Daily and weekly FEV1 changes before and after
exacerbations
For all patients combined (triple therapy and dual
bronchodilation; Fig. 1), FEV1 was fairly stable from 8
to 3 weeks before the first moderate/severe exacerba-
tion using the average of the stable period Week − 8 to
Week − 6 (i.e. Days − 56 to − 36) as baseline. Mean FEV1
in this baseline period was 0.907 L. Looking at the change
from this baseline revealed a pronounced drop in FEV1
that began in the 2 weeks prior to the exacerbation. While
the 90% confidence interval (CI) for the change included
zero for all days before Day − 14, from Day − 14 onwards
the 90% CI was below zero, indicating a drop in FEV1.
FEV1 decreased from − 0.58% (90% CI: -1.67, 0.53; absolute
value − 7mL) on Day − 15 to − 1.91% (90% CI: -2.96, − 0.86;
absolute value − 18mL) on Day − 14, and dropped down
to − 2.06% (90% CI: -3.42, − 0.71; absolute value − 21
mL) on Day − 7 and − 4.79% (90% CI: -6.26, − 3.32;
absolute value − 47mL) on Day 0. On Day 2 of the exacer-
bation, FEV1 dropped to its lowest value: − 6.65% (90%
CI: -8.06, − 5.23) below the stable period 6–8 weeks
before the exacerbation (absolute drop − 69 mL). Fol-
lowing the first day of the exacerbation, FEV1 improved
over approximately 14 days, after which stable levels were
observed. Notably, post-exacerbation lung function did
not reach the pre-exacerbation levels (36–56 days after ex-
acerbation, mean FEV1 0.875 L; Fig. 2).
We also examined moderate exacerbations and severe
exacerbations separately (Fig. 1). For both exacerbation
types, change from baseline in lung function remained
stable from 8 to 3 weeks before the first exacerbation. At
around 2 weeks before the exacerbation, lung function
declined until the exacerbation, and did not recover to
pre-exacerbation levels within 8 weeks after the start of
the exacerbation (Figs. 1b & c and 2). The magnitude of
the mean fall in FEV1 before exacerbation to the first
day of exacerbation was − 48 mL (− 5.08%), dropping to
Fig. 2 FEV1 before, during and after moderate/severe exacerbations, moderate exacerbations and severe exacerbations. FEV1, forced expiratory volume in 1 s
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Fig. 1 a Percentage change from period baseline in on-treatment daily FEV1 before and after first moderate/severe exacerbation. b Percentage change
from period baseline in on-treatment daily FEV1 before and after first moderate exacerbation. c Percentage change from period baseline in on-treatment
daily FEV1 before and after first severe exacerbation. All graphs show both treatments combined. Plots include patients whose first exacerbation after the
ICS withdrawal visit was neither preceded by an exacerbation of any severity in 8weeks prior nor followed by a further exacerbation of any severity within
8weeks (56 days) after exacerbation. Day 0 is the day of the exacerbation. Period baseline is the mean of Days − 56 to − 36. FEV1, forced expiratory
volume in 1 s; ICS, inhaled corticosteroids; SE, standard error
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a low of − 66 mL (− 6.36%) on Day 2 for moderate exac-
erbations, and − 39mL (− 2.63%) with a further drop to
− 85 mL (− 8.77%) on Day 2 of the exacerbation for se-
vere exacerbations (Figs. 1b & c and 2).
Mean change in on-treatment weekly FEV1 before and
after the first moderate/severe, moderate or severe exac-
erbations, for both treatments combined, followed simi-
lar patterns to the daily data (Fig. 3).
FEV1 changes by treatment group
For all moderate/severe exacerbations, when the treat-
ment groups were plotted separately (Fig. 4), a similar
pattern emerged as for the lung function changes in the
combined treatment group (Fig. 1). There was a slightly
larger drop in FEV1 in the dual bronchodilator group
than in the triple therapy arm in the days after the
exacerbation, but after 7 days the change in lung func-
tion was similar in the two groups.
Discussion
This is the first study to show a decrease in daily-measured
lung function before an exacerbation in a large group of pa-
tients with severe COPD and a low FEV1 at baseline (33%
predicted). This decrease in FEV1 was observed from
approximately 2 weeks before the start of an exacerbation,
and although improvements were seen post-exacerbation,
FEV1 did not recover to pre-exacerbation levels up to 8
weeks after the start of the exacerbation. The
post-exacerbation FEV1 levels could either reflect the fact
that the drop in FEV1 never recovered, did not recover
within 8 weeks after the start of the exacerbation, or that
there was progressive lung function decline over time.
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Fig. 3 a Change from Week − 8 in on-treatment weekly FEV1 before and after first moderate/severe exacerbation. b Change from Week − 8 in on-treatment
weekly FEV1 before and after first moderate exacerbation. c Change from Week − 8 in on-treatment weekly FEV1 before and after first severe exacerbation. All
graphs show both treatments combined. Plots include patients whose first exacerbation after the ICS withdrawal visit was neither preceded by an
exacerbation of any severity in 8weeks prior nor followed by a further exacerbation of any severity within 8weeks (56 days) after exacerbation. Patients had
weekly means available for the entire period of interest. FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroids; SE, standard error
Fig. 4 Percentage change from period baseline in on-treatment daily FEV1 before and after first exacerbation by treatment group. Plot includes patients
whose first moderate or severe exacerbation after the ICS withdrawal visit was neither preceded by an exacerbation of any severity in 8 weeks prior nor
followed by a further exacerbation of any severity within 8 weeks (56 days) after exacerbation. Day 0 is the day of the exacerbation. Period baseline is
the mean of Days − 56 to − 36. FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroids; SE, standard error
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Interestingly, another analysis of a large clinical trial has
shown that the rate of lung function decline increases fol-
lowing a single exacerbation [16].
There are limited data in which the daily lung func-
tion around the time of an exacerbation has been stud-
ied, though our results are consistent with previous
studies that have shown that exacerbations are associ-
ated with loss in lung function [1–3]. One other study
that did report daily lung function was published by
Seemungal et al. [4] – a study in which a cohort of
101 patients recorded daily PEFR measurements over
2.5 years. In their cohort, there was no change in
PEFR in the days prior to an exacerbation, unlike the
results presented here. The PEFR results did, however,
show incomplete recovery of lung function [4], as was
observed in this WISDOM analysis. Another study
that measured PEF before and after exacerbations
showed a small drop in PEF prior to the exacerba-
tions that then returned to pre-exacerbation levels
within 2 weeks of the exacerbation; however, increased
symptoms were still seen 4–8 weeks after the exacer-
bation [17].
Interestingly, another small study measured lung func-
tion at baseline and during an exacerbation in a severe
COPD population similar to ours, and found a 40mL
drop in FEV1 at the time of the exacerbation [18], an ob-
servation consistent with our results.
The daily lung function data also show that the
time course of the changes in lung function around
exacerbations was similar in patients who withdrew
from ICS to those in patients who continued ICS.
This suggests that the objective change associated
with an exacerbation occurring during ICS treatment
was similar to that experienced when this therapy
was not used.
The main limitation of the analysis is that it only
included patients who could continue to perform
home-based spirometry manoeuvres during and after their
exacerbation, and patients with more severe symptomatic
exacerbations may be more likely to stop performing the
home-based measurements. It is possible that prior to
more severe exacerbations the drop in FEV1 may be more
pronounced. However, the demographics of the patients
included in this analysis are similar to the demographics
of the wider WISDOM population. Another limitation of
this study is the inherent variability in FEV1, as the repeat-
ability of the measure in individuals is greater than the dif-
ferences we observed [19]. This raises questions about the
possibility of using the drop in lung function as a predict-
ive measure, but does not contradict our findings about
the drop in group mean FEV1.
One strength of the analysis is that, unlike in observa-
tional data, maintenance therapy was standardized. The
WISDOM study offers a unique opportunity to closely
study the daily lung function of a relatively large number
of patients before, during and after exacerbations of COPD
occurring during triple therapy compared with dual
bronchodilation.
Identifying exacerbations before they fully develop could
improve their treatment. Although blood eosinophil count
and exacerbation history can both identify patients at in-
creased risk of exacerbation [13, 20–22], it remains diffi-
cult to predict exacerbations of COPD. It is unlikely
that all COPD exacerbations could be predicted by a
drop in FEV1 before the event, but it is possible that
there is a subset of exacerbations that could be identi-
fied by daily home-based spirometry [14] in patients at
high risk of exacerbations. Future work is needed to
identify cut-offs and to develop algorithms for predic-
tion of exacerbations.
Conclusions
Overall, a small loss in lung function is observed in pa-
tients with severe COPD in the 2 weeks prior to the onset
of symptoms of an exacerbation, and mean FEV1 did not
fully recover 8 weeks after the start of the exacerbation.
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